Skip to content
FrontierPicks

Dormant

CEVA · CEVA, Inc.

Conviction · MEDIUM Cyclical recovery Catalyst · AI chips & memoryPhysical AI & robotics

Last analysed ·

Resolved Graded and closed 2026-06-25 at medium conviction — the published kill line fired. Coverage continued after the close; the read below is dated 2026-09-20 and is not part of the scored record. Research has since re-rated the name low; the record keeps the graded tier.

Current thesis

Edge-AI IP momentum leg has broken: June's reclaim to within ~3% of the $51.60 high failed, and the mid-July AI-capex scare (Moonshot model) drove shares back through the ~$44 base to the mid-$30s. Sell-side still carries $48–$55 targets, but the tape is rolling over into a binary 2026-08-10 Q2 print — a stand-aside, not a momentum entry.

Kill line

A weekly close below $34 breaks the July support shelf (July-25 low $35.85) and confirms the failed-breakout unwind toward the low-$30s/high-$20s; a secondary flag is the edge-AI/physical-AI licensing theme cooling to dead as the mid-July AI-capex scare keeps semis under distribution and target revisions stall.

Pick status

Invalidated resolved published kill line fired graded at medium · since re-rated low How this is scored →

Latest analysis and events for CEVA —

As of 20 September 2026, the latest FrontierPicks analysis for CEVA, Inc. (CEVA): Edge-AI IP momentum leg has broken: June's reclaim to within ~3% of the $51.60 high failed, and the mid-July AI-capex scare (Moonshot model) drove shares back through the ~$44 base to the mid-$30s. Sell-side still carries $48–$55 targets, but the tape is rolling over into a binary 2026-08-10 Q2 print — a stand-aside, not a momentum entry.

Kill line: A weekly close below $34 breaks the July support shelf (July-25 low $35.85) and confirms the failed-breakout unwind toward the low-$30s/high-$20s; a secondary flag is the edge-AI/physical-AI licensing theme cooling to dead as the mid-July AI-capex scare keeps semis under distribution and target revisions stall.

Next dated event on file: — catalyst in 16d.

Current Thesis

Ceva’s recovery thesis rests on wireless and edge artificial-intelligence licensing converting into royalties; the next quarterly results must confirm that conversion before a weekly close below $26.95 invalidates the recovery. The 2026-09-18 adjusted close was $30.27, above the $26.95 close documented on 2026-09-04, but still below the prior thesis’s $34 threshold. The earlier momentum thesis has already failed; the present case requires operating confirmation.

The material change since the 2026-09-06 note is Ceva’s 2026-09-09 ultra-wideband (UWB) collaboration with LG Electronics, which already has an unnamed U.S. semiconductor customer. That ends the earlier absence of company announcements, although the release discloses neither contract revenue nor a royalty commencement date. Ceva’s collaboration announcement

As an analytical classification, the narrative is maturing — the 2026-09-09 customer adoption advances an existing licensing story whose royalty revenue grew only 1% year over year in Q2, reported on 2026-08-10. That combination supports a commercial-conversion case, but does not establish accelerating investor participation. Q2 results

Bullish and bearish views on CEVA, Inc.

The model's bull view on CEVA, Inc. (CEVA), in brief: Customer adoption supports commercial relevance. The bear view: Royalty growth remains limited. Q2 2026 royalty revenue was $10.8 million, up 1% year over year and 17% sequentially, in the 2026-08-10 results. A single sequential improvement is too small a sample to establish a sustained ramp. Q2 results The collaboration lacks financial… Both cases follow in full.

Bull Case

  • Customer adoption supports commercial relevance. The 2026-09-09 LG announcement identifies an existing semiconductor customer for the combined UWB offering. The inference is that the collaboration has progressed beyond a technical demonstration; its financial contribution remains undisclosed. Company announcement
  • Licensing provides a measurable foundation. Q2 2026 licensing and related revenue reached $18.2 million, up 21% year over year, with ten licensing agreements, according to the 2026-08-10 release. Those reported agreements support the conversion thesis; they do not establish the timing of future royalties. Q2 results
  • Management raised the revenue hurdle. On the 2026-08-10 earnings call, management raised expected FY2026 revenue growth to 13–15% and guided Q3 revenue to $30.5–$34.5 million. Those are management forecasts, with a Q3 result below $30.5 million or reduced annual guidance contradicting the operating case.

Bear Case

  • Royalty growth remains limited. Q2 2026 royalty revenue was $10.8 million, up 1% year over year and 17% sequentially, in the 2026-08-10 results. A single sequential improvement is too small a sample to establish a sustained ramp. Q2 results
  • The collaboration lacks financial terms. Ceva’s 2026-09-09 release does not quantify the LG collaboration’s contract value, production volumes or royalty schedule. Customer adoption therefore cannot substantiate a near-term revenue estimate. Company announcement
  • The broader price damage persists. At the 2026-09-18 reference close of $30.27, the adjusted series remained 39.5% below its $50.06 52-week high and had declined 37.5% over three months. The recent recovery has not erased that measured deterioration.

Setup & Price Structure

The 2026-09-18 14-day relative strength index (RSI) was 69.3. That measures recent price momentum; it does not identify retail participation, institutional accumulation or crowded ownership. Moving-average levels, trading-volume confirmation and current ownership-flow measurements are missing, so neither a moving-average breakout nor a crowding verdict is established.

The $26.95 close on 2026-09-04 supplies a dated reference for testing whether the subsequent recovery survives. It is a historical close, not a demonstrated support shelf: the available observations are too sparse to establish repeated support. A weekly close below $26.95 would invalidate this recovery thesis.

Catalyst Calendar (next 30 days)

  • 2026-10-06 — Design Solution Forum. Ceva lists participation in Yokohama, Japan, on its events page checked 2026-09-20. The listing provides a dated industry appearance, but promises no financial update; attendance alone cannot establish royalty conversion. Ceva events

The 2026-09-10 StoneX conference date has passed. As checked on 2026-09-20, Ceva’s press index lists a 2026-09-15 leadership appointment as its latest release and contains no Q3 2026 earnings scheduling announcement. The next quarterly report remains the fundamental test, but its company-confirmed date is missing. Ceva press releases

What Would Change Our Mind

Loss of the September recovery would end the price thesis: a weekly close below $26.95 would undercut the documented 2026-09-04 reference close. This condition replaces the already-breached $34 threshold from the earlier momentum thesis.

For this recovery case to play out, the next Q3 report must show royalty revenue above Q2’s $10.8 million, total revenue at least equal to the $30.5 million lower end of management’s 2026-08-10 guidance, and retention of the 13–15% FY2026 growth outlook before the price condition fires. These are explicit research tests, not additional company guidance. Royalty revenue at or below $10.8 million, a revenue miss or reduced annual guidance would reject that operating confirmation.

Correlation Notes

This is a single-company conversion case. Ceva’s 2026-09-09 collaboration addresses automotive, industrial and consumer applications, while its 2026-08-10 Q2 release reported company-specific licensing and royalty results. Those disclosures do not establish dependence on a broad semiconductor rally. Collaboration announcement, Q2 results

The 2026-09-18 price snapshot contains no matched semiconductor-index return series. A numerical correlation, or a claim that sector flows caused the recovery, is therefore unsupported.

Notes

  • Non-GAAP EPS excludes stock-based compensation and amortization; the GAAP diluted result was $(0.10) in Q2 2026 — compare like with like across quarters.
  • Revenue splits deal-timed, lumpy licensing from lagging per-unit royalties, so a single quarter's total revenue is a weak read on end demand.
  • High-beta small cap: group-level AI and semiconductor headlines move the shares more than company-specific news.
  • Levels here use the split/dividend-adjusted series (52-week high $50.06); unadjusted quote vendors show slightly higher prints for the same days.
  • US-listed with a large Israel-based R&D footprint; management flagged FX headwinds on the 2026-08-10 call.
  • Officer RSU vests in February and August create a recurring Rule 144 sale window; filed notices are intent, not proof of execution.

Related · shared themes

See also · stocks to watch